Clinical trial
Safety Study of PT-523 in Cancer Patients to Treat Solid Tumors Including a…
NCT00088023 · Spectrum Pharmaceuticals, Inc, Industry · Terminated
Key facts
| NCT number | NCT00088023 |
|---|---|
| Title | Safety Study of PT-523 in Cancer Patients to Treat Solid Tumors Including a Preliminary Assessment of Effectiveness |
| Official title | A Phase I Study of PT-523 in Patients With Solid Tumors |
| Lead sponsor | Spectrum Pharmaceuticals, Inc, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | PT-523 for Injection |
| Enrollment | 40 |
| Start date | Mar 1, 2004 |
| Completion | Dec 1, 2005 |
| First posted | Jul 20, 2004 |
| Last update posted | Mar 31, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: